Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalMental HealthBehavioral InterventionsTrial Update

Trial Comparing Behavioral Activation to Relapse Prevention for Veterans with AUD and PTSD

This trial is significant as it explores innovative treatment options for veterans suffering from co-occurring AUD and PTSD, a demographic that often faces unique challenges in mental health care. The outcomes could reshape clinical practices and funding priorities in mental health interventions for this population.

Published: June 11, 2026
Updated: June 11, 2026
Author: Humanexa Intelligence
Therapeutic area: Mental Health / Behavioral Interventions
Asset: Trial
Technology / Platform: Behavioral Activation
Trial SummaryCLN

Phase III

Mental Health / Behavioral Interventions

Status

Active

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

This trial is significant as it explores innovative treatment options for veterans suffering from co-occurring AUD and PTSD, a demographic that often faces unique challenges in mental health care. The outcomes could reshape clinical practices and funding priorities in mental health interventions for this population.

Why it matters

This trial is significant as it explores innovative treatment options for veterans suffering from co-occurring AUD and PTSD, a demographic that often faces unique challenges in mental health care. The outcomes could reshape clinical practices and funding priorities in mental health interventions for this population.

What changed

Trial Update

Analysis

This clinical trial aims to adapt and evaluate Behavioral Activation for veterans with co-occurring AUD and PTSD against Relapse Prevention.

This trial is significant as it explores innovative treatment options for veterans suffering from co-occurring AUD and PTSD, a demographic that often faces unique challenges in mental health care. The outcomes could reshape clinical practices and funding priorities in mental health interventions for this population.

Monitor results on feasibility and acceptability of Behavioral Activation, as well as any significant outcomes related to AUD/PTSD recovery.

Related companies & assets

Assets

  • Trial →
  • U.S. military veterans →
  • Relapse Prevention →
  • mental health funding agencies →

Sources & Humanexa intelligence

Source links

  • Adapting and Piloting Behavioral Activation for Veterans With Alcohol Use Disorder and Posttraumatic Stress Disorder ↗
  • Trial Comparing Behavioral Activation to Relapse Prevention for Veterans with AUD and PTSD ↗

Related Humanexa pages

  • Trial Comparing Behavioral Activation to Relapse Prevention for Veterans with AUD and PTSD →

Related signals

Trial SummaryCLN

Phase III

gastric cancer therapies

Status

Active

Signal Score

8.4

Clinicalhigh signal

FTO/BCL6 Axis Identified as Therapeutic Target in Gastric Cancer Progression

FTO-mediated demethylation of BCL6 promotes gastric cancer progression by inhibiting ferroptosis.

June 21, 2026Read signal →
Trial SummaryCLN

Phase III

epithelial ovarian cancer

Status

Active

Signal Score

8.4

Clinicalhigh signal

Targeted PEGylated PLGA Nanoparticles Enhance Hesperidin Delivery in Ovarian Cancer

Hesperidin-loaded PEGylated PLGA nanoparticles demonstrate improved dissolution and cytotoxicity in EOC models.

June 21, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.